文献速递贫血与红细胞疾病

缺铁女性连续日与隔日口服铁剂及单次晨服与分次服用的铁吸收比较:两项开放标签随机对照试验

Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials.
PubMed 文献 · Lancet Haematol · 2017-10-09

两项在瑞士缺铁女性中开展的开放标签随机对照试验显示,隔日补铁较连续日补铁累积铁吸收更高,分次补铁较单次晨服并未提高铁吸收且升高血清铁调素;作者认为隔日单次补铁可能更优,但需在缺铁性贫血患者中验证。

要点

  • 缺铁女性隔日补铁较连续日补铁累积铁吸收更高,血清铁调素更低。
  • 分次补铁较单次晨服未提高铁吸收,但血清铁调素更高。
  • 两项研究均未报告3级或4级不良事件。

核心结论

  • 在缺铁女性中,每日分次补铁升高血清铁调素并降低铁吸收;隔日单次补铁可优化铁吸收,可能是更优的补铁方案,但需在缺铁性贫血患者中验证。

研究设计与样本

  • 两项前瞻性、开放标签、随机对照试验,使用(54Fe)、(57Fe)或(58Fe)标记的硫酸亚铁评估铁吸收,研究对象为从苏黎世联邦理工学院和苏黎世大学招募的18-40岁、血清铁蛋白≤25 μg/L的缺铁女性。
  • 研究1:40名女性于2015年10月15-29日入组,按1:1随机分为连续日组21例和隔日组19例;连续日组连续14天每日0800时(±1小时)给60 mg铁,隔日组隔日给相同剂量共28天。
  • 研究2:20名女性于2015年8月13-18日入组,按血清铁蛋白分层分为两组各10例;一组每日0800时(±1小时)单次给120 mg铁,另一组分两次于0800时(±1小时)和1700时(±1小时)各给60 mg,连续3天;末次给药14天后交叉至另一方案,进行个体内比较。
  • 两项研究的共同主要结局为铁生物利用度(总铁吸收和分数铁吸收,于给药14天后测定红细胞中同位素标记丰度)和血清铁调素;分组未设盲,主要分析和安全性分析按意向性治疗进行。

主要发现

  • 研究1治疗结束时(连续日组14天、隔日组28天),累积分数铁吸收几何均值(-SD,+SD)为连续日组16.3%(9.3,28.8)vs 隔日组21.8%(13.7,34.6),p=0.0013;累积总铁吸收为连续日组131.0 mg(71.4,240.5)vs 隔日组175.3 mg(110.3,278.5),p=0.0010。
  • 研究1两组补铁最初14天内,连续日组血清铁调素高于隔日组(p=0.0031)。
  • 研究2第1-3天分数铁吸收几何均值:单次每日组11.8%(7.1,19.4)vs 分次每日组13.1%(8.2,20.7),p=0.33;总铁吸收:单次每日组44.3 mg(29.4,66.7)vs 分次每日组49.4 mg(35.2,69.4),p=0.33,两种给药方案间无显著差异。
  • 研究2分次给药组血清铁调素浓度高于单次每日组(p=0.013)。
  • 两项研究均未报告3级或4级不良事件。

临床怎么用

  • 作者认为,在缺铁女性中隔日单次补铁可优化铁吸收,可能是更优的补铁方案。
  • 作者指出这些发现应在缺铁性贫血患者中验证。

局限性

  • 作者指出这些发现应在缺铁性贫血患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines to treat iron deficiency recommend daily provision of ferrous iron divided through the day to increase absorption. However, daily dosing and split dosing might increase serum hepcidin and decrease iron absorption from subsequent doses. Our study aim was to compare iron absorption from oral iron supplements given on consecutive versus alternate days and given as single morning doses versus twice-daily split dosing. METHODS: We did two prospective, open-label, randomised controlled trials assessing iron absorption using (54Fe)-labelled, (57Fe)-labelled, or (58Fe)-labelled ferrous sulfate in iron-depleted (serum ferritin ≤25 μg/L) women aged 18-40 years recruited from ETH Zurich and the University of Zurich, Switzerland. In study 1, women were randomly assigned (1:1) to two groups. One group was given 60 mg iron at 0800 h (±1 h) on consecutive days for 14 days, and the other group was given the same doses on alternate days for 28 days. In study 2, women were assigned to two groups, stratified by serum ferritin so that two groups with similar iron statuses could be formed. One group was given 120 mg iron at 0800 h (±1 h) and the other was given the dose split into two divided doses of 60 mg at 0800 h (±1 h) and 1700 h (±1 h) for three consecutive days. 14 days after the final dose, the groups were each crossed over to the other regimen. Within-individual comparisons were done. The co-primary outcomes in both studies were iron bioavailability (total and fractional iron absorption), assessed by measuring the isotopic label abundance in erythrocytes 14 days after administration, and serum hepcidin. Group allocations in both studies were not masked and primary and safety analyses were done on an intention-to-treat basis. The studies were registered at ClinicalTrials.gov, numbers NCT02175888 (study 1) and NCT02177851 (study 2) and are complete. FINDINGS: For study 1, 40 women were enrolled on Oct 15-29, 2015. 21 women were assigned to the consecutive-day group and 19 to the alternate-day group. At the end of treatment (14 days for the consecutive-day group and 28 days for the alternate-day group), geometric mean (-SD, +SD) cumulative fractional iron absorptions were 16·3% (9·3, 28·8) in the consecutive-day group versus 21·8% (13·7, 34·6) in the alternate-day group (p=0·0013), and cumulative total iron absorption was 131·0 mg (71·4, 240·5) versus 175·3 mg (110·3, 278·5; p=0·0010). During the first 14 days of supplementation in both groups, serum hepcidin was higher in the consecutive-day group than the alternate-day group (p=0·0031). In study 2, 20 women were enrolled between Aug 13 and 18, 2015. Ten women were assigned to receive once-daily dosing and ten were assigned to receive twice-daily divided dosing. No significant differences were seen in fractional (day 1-3 geometric mean: 11·8% [7·1, 19·4] once daily vs 13·1% [8·2, 20·7] twice daily; p=0·33) or total iron absorption (day 1-3: 44·3 mg [29·4, 66·7] once daily vs 49·4 [35·2, 69·4] twice daily; p=0·33) between the two dosing regimens. Twice-daily divided doses resulted in a higher serum hepcidin concentration than once-daily dosing (p=0·013). No grade 3 or 4 adverse events were reported in either study. INTERPRETATION: In iron-depleted women, providing iron supplements daily as divided doses increases serum hepcidin and reduces iron absorption. Providing iron supplements on alternate days and in single doses optimises iron absorption and might be a preferable dosing regimen. These findings should be confirmed in iron-deficient anaemic patients. FUNDING: Swiss National Science Foundation, Bern, Switzerland.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017. PMID: 29032957. doi:10.1016/S2352-3026(17)30182-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。